Friederike Holze

New week — new luck — new TWiNPP 🧠
#ThisWeekInNPP: four studies on genetics, development, neurogenesis, and neuropsychiatric models.
🧵👇

Leah Mayo | Top 40 Under 40 2025 - Avenue Calgary Leah Mayo’s groundbreaking work developing therapeutic applications of psychedelics and cannabis-related drugs as the first research chair in psychedelics in Canada is advancing mental health care.

🎉 Congratulations to our Social Media Editor, Dr. Leah Mayo, on being named to Avenue Calgary’s Top 40 Under 40!
Her research on stress, cannabinoids, psychedelics, and mental health continues to make an impact - in and beyond the lab.
🔗 www.avenuecalgary.com/top-40-under...

🧠 Currently underway: a deep dive into how psychedelics induce neural plasticity 🧩 and enhance mental health.
#ECNP2025 #MentalHealth #psychedelics Friederike Holze

The effect of methamphetamine and 3,4-methylenedioxymethamphetamine on peripheral endocannabinoid concentrations: a study in healthy adults - Psychopharmacology Rationale Stimulant drugs such as methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) can impact neurobiological systems implicated in stress, reward processing, and drug use. Although recent preclinical evidence implicates the endocannabinoid (eCB) system in these processes, little is known about the acute effects of stimulants on eCB levels in humans. Objectives The aim of the present study was to investigate the effects of acute administration of the prototypical psychostimulant MA and the psychostimulant-empathogen MDMA on circulating eCB levels in healthy adults. Methods Using a within-subject, double-blind design, this study assessed the acute effects of MA (20 mg), MDMA (100 mg), and placebo on plasma eCB levels in healthy human participants (N = 22) during three separate sessions. Blood samples assessing concentrations of the eCBs anandamide (AEA) and 2-Arachidonoylglycerol (2-AG) were collected between 150- and 180-minutes post-drug administration, and subjective measures of drug effects were collected at regular intervals. Results MA, but not MDMA, was associated with significantly lower 2-AG plasma concentrations compared to placebo. Neither drug impacted AEA concentrations. However, during the placebo condition, higher AEA concentrations were correlated with disliking the ‘drug effects’, suggesting a possible relationship between AEA levels and negative expectations of subjective drug effects. Conclusions These findings provide novel insights into how stimulant drugs act on the eCB system and may help to develop treatments for SUDs.

Congrats to @pact-lab.bsky.social PhD student @anadeutsch.bsky.social on her 1st first-author paper from the lab! 🎉

She explored how MDMA & methamphetamine impact cortisol, endocannabinoids, & BDNF levels in healthy humans and how this relates to the subjective drug experience 💊👇

Another great psychedelics panel (I know what I like), chaired by @anadeutsch.bsky.social with presentations by her on data @hannamolla.bsky.social and I collected with Dr de Wit, Dr. Gibson Cook and Dr Helena Aicher #EBPS2025

What a perfect ending of #EBPS2025 super proud that I was the chair of this wonderful panel presenting their beautiful work on acute and chronic #cannabis effects. Excellent work @connorhaggarty.bsky.social @zivacooper.bsky.social Amir Englund & Lukas Eggeneberger 🤩

I had the pleasure of attending a psychedelics masterclass this afternoon chaired by Harriet de Wit with talks from Kathryn Cunningham, Chuck Nichols, @drfriid.bsky.social & @mayoonthebrain.bsky.social. From molecules to behaviour and practical steps in trial design #EBPS2025

Don't forget - poster abstract submissions for #ACNP2026 are due *this Thursday*, August 28th ⌛️

We still don’t know if microdosing psychedelics is effective or a placebo, but is it safe? Could microdosing activate cardiac 5HT2B receptors and cause valvulopathy? New work online at pubs.acs.org/doi/pdf/10.1... from @deffinger.bsky.social suggests that - at least in mice - the answer is no. 1/

Et si les champignons hallucinogènes devenaient un traitement efficace contre l’alcoolisme et la dépression ? La recherche s’intéresse aux pouvoirs de la psilocybine – et autres psychédéliques interdits en usage clinique – sur les addictions et les dépressions.

📰 Another one! Le Point adds to the wide media coverage of our Psilocybin–Alcohol–Depression study. l.lepoint.fr/DYL
France’s 1st psychedelic renaissance trial shows:
✨ society’s demand for new options as psychiatry & addiction care hit limits
✨ the need for rigorous science to test them.

Don't miss this 🆕 NPP Commentary on menstrual cycle and mental health in adolescents from @sibelnayman.bsky.social & Hannah Klusmann

Welcome to our newest @npp-journal.bsky.social Associate Editor, Dr. Kate Fitzgerald from @columbiapsych.bsky.social

Be sure to check out our "Meet the Editor" episode with Dr. Fitzgerald below ⤵️

Want to be the next @npp-journal.bsky.social Editorial Intern?

Or want to know more about what an Editorial Intern even does?

Then check out the below thread and submit your application by July 30th! 👇

Another week is upon us, so it's time to check out what's new #ThisWeekInNPP

We have an all dopamine lineup, see below for the latest in data-driven #dopamine insights ⤵️

The 2024 Impact Factors are out and we're happy to see NPP moving up to a 2024 Impact Factor of 7.1 🎉

We are grateful to the authors, reviewers, and editors who have contributed to so many stellar manuscripts this past year...and please, keep that 🔥 data coming!

We're back with another installment of #ThisWeekinNPP! ICYMI, every week we recap the latest articles from #NPP 🧐

#TWiNPP

An international Delphi consensus for reporting of setting in psychedelic clinical trials - Nature Medicine A large international panel of experts reach consensus on a new standard for reporting settings in psychedelic trials, identifying 30 key non-pharmacological factors to strengthen the rigor of psyched...

New in @naturemedicine.bsky.social
"An international Delphi consensus for reporting of setting in psychedelic clinical trials" by Chloé Pronovost-Morgan, Kyle Greenway, myself, and many ReSPCT Experts." nature.com/articles/s41...

YouTube video by NPP Journal npp's "Meet the Author" with Dr. Francesco Bavato

Our latest "Meet the Author" interview with Dr. Francesco Bavato gives you the story behind how gamma-hydroxybutyrate (GHB) impacts sleep in MDD (interview by @brikchen.bsky.social & @drfriid.bsky.social )

Link to paper: www.nature.com/articles/s41...

www.youtube.com/watch?v=SiKN...

We welcome you back from the long weekend (or - if outside the US - just a regular weekend) with what's new #ThisWeekInNPP

See below for eCB-based interventions for PTSD, stress & sleep interactions, NMDA antagonists & working memory, plus info on a new cohort study⤵️

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study Lysergic acid diethylamide (LSD) is currently being investigated as a potential treatment for psychiatric and neurological disorders. Different LSD formulations (base or tartrate, oral or intravenous...

🔥New Paper🔥 Happy to share our latest research describing the oral bioavailability of #LSD for the first time and comparing different oral formulations #psychedelics

doi.org/10.1002/cpt....

#ThisWeekInNPP
New week – new science! 🧠
Explore the latest in neuropsychopharmacology research — from opioids to antipsychotics to recent findings on PTSD. 🧵👇

Congrats to @npp-journal.bsky.social whose podcasts were ranked #5 for Best Clinical Research Podcasts bit.ly/3RUupjJ and #10 for the Best Pharmacology Podcasts bit.ly/4k5Pcgb! All NPP podcast can be found at www.nature.com/npp/podcast

Symposium 2 explores the innovations and challenges in psychedelic research and how these advances are improving our understanding of behaviour and various mental health conditions chaired by Kathryn Cunningham #EBPS2025

Listen up 📢 it's time for another rundown of what's new #ThisWeekInNPP

See below the latest science regarding nicotine smoking, cannabis use, ketamine, neuropathic pain, Parkinson's disease vulnerability, MDD & more (seriously - it's a 2-pager this week)⤵️

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial Despite the promising therapeutic effects of psilocybin, its efficacy in preventing relapse after withdrawal treatment for alcohol use disorder (AUD) …

Hi everyone, if you are interested in #psychedelic-assisted therapy, we just published a new study: www.sciencedirect.com/science/arti.... Congratulations to Dr. Nathalie Rieser, who has done a terrific job spearheading this project.

Gather 'round - it's time for a 2-part edition of #ThisWeekInNPP

See below for updates on ketamine, THC, stress-coping, mania, social threat and more 👇

1st National Symposium of the Psychedelic Medicine Section - AFPBN SCHEDULE OF THE DAY Click here to discover the program Click here to register ! Date : June 5, 2025 Location : Paris Brain Institute, 47 boulevard de l’Hôpital, 75013 PARIS The 1st National Symposium ...

📣📣📣 I am very happy to announce the first edition of the National Symposium of the #Psychedelic Medicine Section of the #AFPBN, taking place on Thursday, June 5th, 2025, at the Paris Brain Institute.
www.afpbn.org/1st-national...

Check out the newest Brainpod Podcast on Endocannabinoid contributions to the perception of socially relevant, affective touch in humans a new study published in @npp-journal.bsky.social - bit.ly/Brainpod

Full Study: go.nature.com/4hcjlbI

@mayoonthebrain.bsky.social @connorhaggarty.bsky.social

It's time for another roundup of what's going on #ThisWeekInNPP

See below for new articles on sleep in TRD 😴, alcohol & taste/smell 🧠 networks, neural mechanisms of behavioral flexibility in 🐀, novel ADHD treatments💊 & social stress in prairie vole relationships 💔

Check out what's new #ThisWeekInNPP - including novel insights into mechanisms underpinning clozapine's effects, interactions between methamphetamine and serotonin, & neural signatures of late-life depression ⤵️